Abstract: The present disclosure provides a series of dihydroisoquinoline compounds or a pharmaceutically acceptable salt, ester, isomer, solvate, hydrate, prodrug, or isotopically labeled compounds thereof, having the structure of general formula I: (I). The compounds have an extremely strong activity for inhibiting Hepatitis B surface antigen and has an extremely strong activity for inhibiting Hepatitis B virus DNA. In addition, the compounds feature high bioavailability and can exhibit efficacy with a low dosage, which reduces the potential toxicity of the compounds.